Funding
Series A · Biotech

Beyang Therapeutics raises $30M Series A

Beyang Therapeutics raised $30 million in Series A financing announced in August.

Updated Oct 16, 2026By RoundOS Funding desk

Backers include Legend Capital, Shanghai Healthcare Capital, China Medical System Holdings, Fenglei Capital, Shanghai Sci-Tech Innovation Center Capital, Harbor & Canton Capital, Root Venture Partners and YuanBio Venture Capital.

The company uses its ExCEED molecular-design platform in drug discovery.

Funding history

Series A · This round$30M

Sources

  1. Beyang Therapeuticsprojectstartups.com
  2. prnewswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Knowledge Work

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.

¥4.8BSeries C debt second close · Oct 23, 2026

Related